Articles tagged with: Maintenance Therapy
Yesterday, the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, was the busiest day of the meeting for people interested in multiple myeloma. Myeloma-related presentations filled the entire morning and afternoon, and sometimes there were even multiple relevant presentations going on simultaneously.
The morning presentations about therapies combining current myeloma drugs will be covered in this update. Morning presentations about potential new myeloma therapies were covered in an update published earlier today, and presentations from the rest of the day will be …
A recent British analysis of data from a major clinical trial found that thalidomide maintenance therapy did not have a uniformly positive impact on overall survival in multiple myeloma patients.
In fact, overall survival for patients in the trial who received thalidomide maintenance was slightly lower than overall survival for patients who did not receive maintenance therapy. The difference, however, was not statistically significant.
In contrast, progression free survival was significantly longer for patients who received thalidomide maintenance compared to patients who were not on a maintenance regimen.
The study …
Results of a recent Italian study suggest that a combination of Velcade and dexamethasone is a safe and effective form of maintenance therapy for relapsed/refractory multiple myeloma patients who responded to Velcade-containing rescue regimens.
“Our study showed that maintenance therapy with Velcade in relapsed / refractory multiple myeloma patients may improve the progression-free survival and overall survival of patients with a low grade of toxicity,” Dr. Giulia Benevolo, lead author of the study, told The Myeloma Beacon.
“[However], this is a Phase 2 trial, and the results must be confirmed …
In a session of the International Myeloma Workshop (IMW) today, multiple myeloma experts presented the latest data about the efficacy of Revlimid maintenance therapy and discussed the drug’s potential link to second cancers.
Results from a study conducted by the Cancer and Leukemia Group B (CALGB) showed that Revlimid (lenalidomide) maintenance therapy following stem cell transplantation significantly extends survival of myeloma patients. Two other studies investigating Revlimid maintenance, the IFM 2005-02 and MM-015 studies, have not yet shown a survival benefit.
All three studies, however, have raised concerns that …
The 13th International Myeloma Workshop will take place Tuesday, May 3, through Friday, May 6, in Paris. During the four-day meeting, multiple myeloma specialists from all over the world will discuss the current understanding of the biology and treatment of myeloma.
Additionally, much awaited data about the safety and effectiveness of Revlimid (lenalidomide) maintenance therapy will be presented at the meeting.
The Myeloma Beacon will be covering the event, so readers can expect many articles during the meeting and in the weeks afterward about the key myeloma findings.